

FEB. 28. 2002 3:00PM, HOLLAND & KNIGHT  
Law Offices

## HOLLAND & KNIGHT LLP

One Atlantic Center  
1201 West Peachtree Street, N.E.  
Suite 2000  
Atlanta, Georgia 30309-3400

404-817-8500  
FAX 404-881-0470  
http://www.hklaw.com

**FAX RECEIVED**

MAR 01 2002

**GROUP 1600**

**FAX RECEIVED**

MAR 01 2002

**FACSIMILE**

**GROUP 1600**

**TO:**

TC 1600 - BEFORE

**FINAL**

NAME

Washington

CITY

United States Patent and

Trademark Office

COMPANY/FIRM

D.C.

STATE

703 872-9306

FAX NUMBER

703 308-0198

(TELEPHONE NUMBER)

**OFFICIAL**

**FROM:**

Patrea L. Pabst

NAME

404 817-8473

TELEPHONE

TOTAL PAGES (Including Cover Sheet)

**FOR THE RECORD:**

DATE: February 28, 2002

URGENCY: ☐ SUPER RUSH

☐ RUSH

☐ REGULAR

FAXED BY:

FILE #: 078230/00017

CLIENT NAME: ICI 101

CONFIRMED: ☐ YES ☐ NO

NAME:

TIME:

If you did not receive all of  
the pages or find that they  
are illegible, please call  
(404) 817-8500

**CONFIDENTIALITY NOTICE:** This facsimile, along with any documents, files, or  
attachments, may contain information that is confidential, privileged, or otherwise  
exempt from disclosure. If you are not the intended recipient or a person responsible  
for delivering it to the intended recipient, you are hereby notified that any disclosure,  
copying, printing, distribution or use of any information contained in or attached to  
this facsimile is strictly prohibited. If you have received this facsimile in error,  
please immediately notify us by facsimile or by telephone collect at the numbers  
stated above, and destroy the original facsimile and its attachments without reading,  
printing, or saving in any manner. Your cooperation is appreciated. Thank you.

**MESSAGE:**

### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Hans Josef Stauss and Liqun Gao

Serial No.: 09/625,963

Art Unit: 1644

Filed: July 26, 2000

Examiner: A. Decloux

For: "IMMUNOTHERAPEUTIC METHODS USING EPITOPES OF WT-1 AND GATA-1"

ATL1 #510744 v1

Received from <404 898 8002> at 2/28/02 3:02:29 PM [Eastern Standard Time]

NO. 1009 P. 1

Annapolis  
Atlanta  
Bethesda  
Boston  
Bradenton  
Chicago  
Fort Lauderdale  
Jacksonville  
Lakeland  
Los Angeles  
Melbourne  
Miami  
New York

Northern Virginia  
Orlando  
Portland  
Providence  
San Antonio  
San Francisco  
Seattle  
St. Petersburg  
Tampa  
Washington, D.C.

**FAX RECEIVED**

FEB 29 2002

**GROUP 1600**

International Offices:  
Caracas  
Helsinki  
Mexico City  
Rio de Janeiro

\*Representative Offices

Applicant(s): Hans Josef Stauss and Liguang Gao  
Serial & Docket No.: 09/625,963  
Filed: July 26, 2000

**FAX RECEIVED**


**FEB 29 2002**

**GROUP 1600**

**CERTIFICATE OF TRANSMISSION UNDER 37 CFR 1.8**

**OFFICIAL**

I hereby certify that an Amendment and Response to Office Action with Certificate of Transmission Under 37 C.F.R. § 1.8(b); Petition for Extension of Time Under 37 CFR 1.136(a) (in duplicate); Fee Transmittal Sheet (in duplicate); copies of U.S. Patent No. 6,348,581 B1, U.S. Patent No. 6,335,424 B1, and pages 122-123 from Cellular and Molecular Immunology (2<sup>nd</sup> edition, Abbas, Lichtman, and Pober, 1994); Transmittal Form; with authorization to charge/credit the Deposit Order Account No. 50-1868; along with any paper referred to as enclosed, is being transmitted via facsimile to TC 1600 (BEFORE FINAL) at (703) 872-9306 within the United States, to the Commissioner for Patents, Washington, D.C. 20231 on the date shown below.

  
Aisha Wyatt

Date: February 28, 2002

ATL1 #510750 v1

ICI 101  
078230/00017

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

# 12/13  
JMA  
3/2/02

**Applicant:** Hans Josef Stauss and Liquan Gao

**Serial No.:** 09/625,963

**Art Unit:** 1645

**Filed:** July 26, 2000

**Examiner:** A. Decloux

**For:** *"IMMUNOTHERAPEUTIC METHODS USING EPITOPES OF WT-1 AND GATA-1"*

Assistant Commissioner for Patents  
Washington, D.C. 20231

**AMENDMENT AND RESPONSE TO OFFICE ACTION**

**Sir:**

Responsive to the Office Action mailed on October 31, 2001, please amend the application as follows. Submitted with this Amendment and Response is a Petition for Extension of Time to extend the period for response one month, to and including February 28, 2002, copies of U.S. Patent No. 6,348,581 B1, U.S. Patent No. 6,335,424 B1, and pages 122-123 from Cellular and Molecular Immunology (2<sup>nd</sup> edition, Abbas, Lichtman, and Pober, 1994) to facilitate examination. The Commissioner is hereby authorized to charge \$270.00 to Deposit Account No. 50-1868. This charge will cover the fee for the one month extension of time and two extra independent claims for a large entity.

Please address all future correspondence to:

**Patrea L. Pabst  
Holland & Knight LLP  
One Atlantic Center, Suite 2000**

509304v1

U.S.S.N. 09/625,963

Filed: July 26, 2000

MARKED UP VERSION OF AMENDMENTS PURSUANT TO 37 C.F.R. § 1.121

peptide comprising at least six consecutive amino acids of SEQ ID NO:1; and variants thereof wherein the side chains of one or two of the amino acids of SEQ ID NO:1 are altered.

*Rule 1.126* ~~43. 39.~~ (New) The peptide of claim 1 comprising the amino acid sequence RMFPNAPYL (SEQ ID NO:1).

*Sub c2* ~~44. 40.~~ (New) The peptide of claim 1 consisting of from 8 to 12 amino acids.

*B5* ~~45. 41.~~ (New) The peptide of claim 1 which is capable of being processed by an antigen presenting cell so that a fragment is produced which is able to bind to HLA-A0201.

~~46. 42.~~ (New) A peptide consisting of from 8 to 12 amino acids and comprising an amino acid sequence selected from the group consisting of RMFPNAPYL (SEQ ID NO:1); a peptide comprising at least six consecutive amino acids of SEQ ID NO:1; and a variant thereof wherein the side chains of one or two of the amino acids of SEQ ID NO:1 are altered.

~~47. 43.~~ (New) A peptide consisting of from 8 to 12 amino acids and comprising an amino acid sequence selected from the group consisting of RMFPNAPYL (SEQ ID NO:1); and a peptide comprising at least six consecutive amino acids of SEQ ID NO:1.

*Rule 1.126* ~~48. 44.~~ (New) The vaccine of claim 19 wherein the cancer is leukaemia, breast, melanoma or ovarian cancer.